Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.99 0.04 (0.5%) Market Cap: 2.24 Bil Enterprise Value: 1.96 Bil PE Ratio: 0 PB Ratio: 3.30 GF Score: 40/100

Iovance Biotherapeutics Inc at JMP Securities Life Sciences Virtual Conference Transcript

Jun 17, 2021 / 06:00PM GMT
Release Date Price: $24.62 (+2.46%)
Reni John Benjamin
JMP Securities LLC, Research Division - MD & Equity Research Analyst

Excellent. Good afternoon, everyone, and welcome to the second day of the JMP Securities Life Sciences Conference. My name is Ren Benjamin, Senior Biotechnology Analyst here. And it's my pleasure to introduce Iovance, in our view, the leader in TIL therapies for solid tumors and a company that's on the cusp of submitting multiple BLAs. Here to tell us more about the company is Igor Bilinsky, COO; and Sara Pellegrino, VP of IR. Welcome, guys, nice to see you. We never really know exactly who's in the audience, whether they know of the Iovance story or not. And so Sara, maybe I'll hand it off to you to give us a quick synopsis of the Iovance story as a whole.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Sure, and thanks so much, Reni, for hosting us today. So Iovance is a late-stage oncology company. We're developing novel cell therapies initially focused on addressing solid tumors for patient populations with significant unmet need.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot